Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
navitoclax + etoposide + cisplatin
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Navitoclax + etoposide + cisplatin is a combination chemotherapy regimen investigated for treatment of various solid tumors, including small cell lung cancer and other malignancies. Navitoclax (ABT-263) is a small molecule inhibitor targeting anti-apoptotic members of the BCL-2 family (BCL-2, BCL-XL, BCL-W), promoting apoptosis in cancer cells. Etoposide is a topoisomerase II inhibitor, causing DNA strand breaks and cell death. Cisplatin is a DNA cross-linking agent that interferes with DNA replication and transcription, leading to apoptosis. The combination leverages the synergistic effects of apoptosis induction (navitoclax), DNA damage (etoposide), and DNA crosslinking (cisplatin) to maximize anti-tumor efficacy, potentially overcoming resistance to single agents. This regimen has undergone early-phase clinical evaluation, including safety and efficacy assessments in multiple cancer types[2][4].
- Other names
- navitoclax + etoposide + cisplatin
02
Targets
Bcl-w (B-cell lymphoma 2-like 2)TOP2A (DNA topoisomerase II)DNABCL2L1 (B-cell lymphoma-extra large protein)
Beyond the preview
Go deeper on navitoclax + etoposide + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on navitoclax + etoposide + cisplatin.